

Appl. No. 10/082,691  
Reply to Office Action of June 24, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method for treating neurogenic inflammation pain, the method comprises administering a therapeutically effective amount of an agent to a patient, the agent comprising a botulinum toxin component ~~conjugated with~~ covalently coupled to a substance P component, thereby treating the neurogenic inflammation pain for at least about two months.

2. (Original) The method of claim 1 wherein the botulinum toxin component comprises an L chain or an HN and an L chain.

3. (Original) The method of claim 2 wherein the HN is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

4. (Original) The method of claim 2 wherein the HN is obtained from botulinum toxin serotype A.

5. (Original) The method of claim 2 wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

Appl. No. 10/082,691  
Reply to Office Action of June 24, 2004

6. (Original) The method of claim 2 wherein the L chain is obtained from botulinum toxin serotype A.

7. (Previously presented) The method of claim 1 wherein the substance P component is substance P.

8. (Previously presented) The method of claim 1 wherein the substance P component is a precursor of substance P having an amino acid sequence selected from the group of consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

9. (Previously presented) The method of claim 1 wherein the substance P component is a substance P functional analogue.

10. (Cancelled)

11. (Cancelled)

12. (Original) The method of claim 1 wherein the pain is arthritis pain.

13-16. (Cancelled)

17. (Previously presented) The method of claim 1 wherein the agent is administered subcutaneously.

18. (Previously presented) The method of claim 1 wherein the agent is administered intramuscularly.

Appl. No. 10/082,691  
Reply to Office Action of June 24, 2004

19. (Previously presented) The method of claim 1 wherein the agent is administered systemically.

20. (Cancelled)

21. (Cancelled)

22. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 20% as determined by the patient based on a pain quantification scale.

23. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 40% as determined by the patient based on a pain quantification scale.

24. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 50% as determined by the patient based on a pain quantification scale.

25. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 60% as determined by the patient based on a pain quantification scale.

26. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 80% as determined by the patient based on a pain quantification scale.

Appl. No. 10/082,691  
Reply to Office Action of June 24, 2004

27. (Previously presented) The method of claim 1 wherein the agent is administered in an amount that will reduce pain in a patient by about 100% as determined by the patient based on a pain quantification scale.

28. (Cancelled)

29. (Cancelled)